Neuberger Berman Group’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.08M Sell
80,434
-77,140
-49% -$8.01M ﹤0.01% 956
2026
Q2
$15.4M Buy
157,574
+98,498
+167% +$8.6M 0.01% 779
2026
Q1
$4.96M Sell
59,076
-28,706
-33% -$1.66M ﹤0.01% 987
2025
Q4
$3.62M Buy
+87,782
New +$3.4M ﹤0.01% 1042

Other funds holding DNTH

Neuberger Berman Group's DNTH Position: Q3 2026 in Review

Neuberger Berman Group reduced its Dianthus Therapeutics (DNTH) stake by 49% in Q3 2026, selling an estimated $8.01M and leaving 80,434 shares worth $7.08M. The position accounts for ﹤0.01% of the portfolio, ranked #956.

Neuberger Berman Group first reported a position in DNTH in Q4 2025 and has held it in 4 quarters since. The position peaked at $15.4M in Q2 2026. 274 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • Neuberger Berman Group held 80,434 shares of Dianthus Therapeutics worth $7.08M as of Q3 2026.
  • Neuberger Berman Group sold 77,140 Dianthus Therapeutics shares in Q3 2026, an estimated $8.01M.
  • Dianthus Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q3 2026, its #956 holding.
  • Neuberger Berman Group first reported a position in Dianthus Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Neuberger Berman Group's Dianthus Therapeutics position peaked at $15.4M in Q2 2026.
  • 274 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Neuberger Berman Group's 13F filing for Q3 2026, filed 13 Nov 2026.